Company intelligence
Benchworks
About Benchworks
Benchworks is a commercialization platform purpose-built for small and mid-sized life science companies. We combine the strategic rigor of a management consultancy, the creative power of a full-service marketing agency, and the analytical precision of a market research firm. Our integrated approach ensures that from early development through launch and beyond, your product is positioned for success. Our team comprises former industry executives, seasoned strategists, and creative professionals who specialize in navigating the complexities of the pharmaceutical and biotech landscapes. Whether it's crafting compelling brand narratives, developing data-driven market strategies, or conducting in-depth research to inform decision-making, Benchworks is your partner in achieving commercial excellence. Benchworks is part of the Danforth Health platform. Learn more about our broader capabilities here: https://www.danforthhealth.com
Verified activity
Signals from Benchworks
3 published signals
Legal & Regulatory
Benchworks reports that Revolution Medicines received FDA approval for its first product, RASONQUE in metastatic pancreatic cancer.
Reported by Benchworks
Legal & Regulatory
Benchworks reports that Priovant received approval for LISRAYA, the first oral targeted treatment for dermatomyositis.
Reported by Benchworks
Legal & Regulatory
Benchworks reports that Outlook Therapeutics is building the financial and operational infrastructure for the U.S. launch of LYTENAVA.
Reported by Benchworks